The 2015 Novo Nordisk Prize Symposium on
Transcription
The 2015 Novo Nordisk Prize Symposium on
The 2015 Novo Nordisk Prize Symposium on Hepatitis C Virus (HCV) Friday the 11th of September, 2015 Lecture Hall, Novo Nordisk Foundation, Tuborg Havnevej 19, DK-2900 Hellerup, Denmark Organized by Prof. Jens Bukh, Copenhagen Hepatitis C Program (CO-HEP) and CEO Birgitte Nauntofte, Novo Nordisk Foundation 8.30 Registration 9.00 Welcome - The 2015 Novo Nordisk Prize Niels-Henrik von Holstein-Rathlou, CSO, Novo Nordisk Foundation 9.15 From Non-A, Non-B to hepatitis C virus – a historical perspective from the mentor Robert Purcell, National Institutes of Health, Bethesda, Maryland, USA 9.45 Infectious culture systems of hepatitis C virus – years in the making Jens Bukh, CO-HEP 10.15 How have humanized mice contributed to our understanding of HCV Philip Meuleman, Ghent University, Ghent, Belgium 10.50 Coffee/tea 11.15 The long journey of hepatitis C virus entry into the hepatocyte Jean Dubuisson, Institut Pasteur, Lille, France 11.50 A new view of virus-microRNA interactions: HCV, miR-122, and beyond Charles Rice, The Rockefeller University, New York, New York, USA 12.25 Viral and host factors in HCV-associated hepatocellular carcinoma Patrizia Farci, National Institutes of Health, Bethesda, Maryland, USA 13.00 Lunch 13.45 Cell culture studies of direct acting antivirals against HCV Judith Gottwein, CO-HEP 14.20 Specificity of the protective B cell response to HCV Steven Foung, Stanford University Blood Center, Palo Alto, California, USA 14.55 Role of CD8+ T cell responses in HBV and HCV infection Robert Thimme, University Hospital of Freiburg, Freiburg, Germany 15.30 Coffee/tea 15.55 Hepatitis C virus neutralizing epitopes and rational vaccine design Mansun Law, The Scripps Research Institute, La Jolla, California, USA 16.30 Comparing immunity against hepatitis viruses: what can be learned from studies of HAV and HEV Christopher Walker, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA 17.05 Closing remarks Jens Bukh, CO-HEP 17.15 End of program
Similar documents
Prophylactic Hepatitis B Virus Vaccines Market : Global Industry Analysis and Forecast 2016 - 2024
The prophylactic hepatitis B virus vaccines market is expected to grow remarkably during the forecast period due to increasing prevalence and incidence of hepatitis B infection, increasing public awareness (Patient Education Programs), government initiatives for promotion and creating awareness about prophylactic hepatitis B vaccines.
More information